Article Information
- Received March 13, 2005
- Revision received June 10, 2005
- Accepted June 14, 2005
- First published July 20, 2005.
- Version of record published July 20, 2005.
Author Information
Author contributions
Disclosures
- Received March 13, 2005.
- Revision received June 10, 2005.
- Accepted June 14, 2005.
This work was supported by the National Multiple Sclerosis Society and National Institutes of Health (NIH) Grant NS46668. We thank Lee Anne Givan and Tarek Fakouri for initiating these experiments and Dr. Bruce Carter for critical comments on this manuscript. The GAL4/UAS transgenic lines were developed in the laboratory of J. Campos-Ortega. The anti-BrdU antibody, developed by S. J. Kaufman, was obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the National Institute of Child Health and Human Development and maintained by The University of Iowa, Department of Biological Sciences (Iowa City, IA). Confocal microscopy was performed using equipment made available by the Vanderbilt University Medical Center Cell Imaging Core Resource, supported by NIH Grants 1S10RR15682, CA68485, and DK20593.
Correspondence should be addressed to Dr. Bruce Appel, Department of Biological Sciences, VU Station B, Box 35-1634, Vanderbilt University, Nashville, TN 37235-1634. E-mail: b.appel{at}vanderbilt.edu.
Copyright © 2005 Society for Neuroscience 0270-6474/05/256836-09$15.00/0
Online Impact